August 23, 2014, 12:30pm
Escalating societal healthcare needs have driven an unprecedented era of biomedical innovation. However, the development of candidate technologies without consideration of a robust regulatory strategy is likely to contribute to stymied patient access and commercial viability. Therefore, this session considered worldwide efforts to rapidly and proportionally develop international regulatory processes to accommodate increasingly heterogeneous and unfamiliar healthcare technologies and their swift translation from lab to bedside.
David Brindley, Research Fellow, University of Oxford/Centre for the Advancement of Sustainable Medical Innovation (Moderator)
Bob Clay, Chief Regulatory Officer, Kinapse & Managing Director, Highbury Regulatory Science
Andrew Martello, Managing Director, Spoonful of Sugar
Evan Snyder, Director, Centre for Stem Cell and Regenerative Medicine, Director, Stem Cell Research Centre and Core Facility, Sanford-Burnham Medical Research Institute